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Abstract
Background: The risk of sporadic colorectal cancer is mainly associated with lifestyle factors and
may be modulated by several genetic factors of low penetrance. Genetic variants represented by
single nucleotide polymorphisms in genes encoding key players in the adenoma carcinoma
sequence may contribute to variation in susceptibility to colorectal cancer. In this study, we aimed
to evaluate whether the recently identified haplotype encompassing genes of DNA repair and
apoptosis, is associated with increased risk of colorectal adenomas and carcinomas.
Methods: We used a case-control study design (156 carcinomas, 981 adenomas and 399 controls)
to test the association between polymorphisms in the chromosomal region 19q13.2-3,
encompassing the genes ERCC1, ASE-1 and RAI, and risk of colorectal adenomas and carcinomas in
a Norwegian cohort. Odds ratio (OR) and 95% confidence interval (CI) were estimated by binary
logistic regression model adjusting for age and gender.
Results: The ASE-1 polymorphism was associated with an increased risk of adenomas, OR of 1.39
(95% CI 1.06–1.81), which upon stratification was apparent among women only, OR of 1.66 (95%
CI 1.15–2.39). The RAI polymorphism showed a trend towards risk reduction for both adenomas
(OR of 0.70, 95% CI 0.49–1.01) and carcinomas (OR of 0.49, 95% CI 0.21–1.13) among women,
although not significant. Women who were homozygous carriers of the high risk haplotype had an
increased risk of colorectal cancer, OR of 2.19 (95% CI 0.95–5.04) compared to all non-carriers
although the estimate was not statistically significant.
Conclusion: We found no evidence that the studied polymorphisms were associated with risk of
adenomas or colorectal cancer among men, but we found weak indications that the chromosomal
region may influence risk of colorectal cancer and adenoma development in women.
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Background
Colorectal cancer (CRC) still is one of the leading causes
of cancer deaths in developed countries and adenomas are
the predominant precursors of this disease [1].
The risk of sporadic CRC is mainly associated with life-
style factors and may be modulated by several genetic fac-
tors of low penetrance [2,3]. Genetic variants represented
by single nucleotide polymorphisms (SNPs) in genes
encoding key players in the adenoma carcinoma sequence
may contribute to variation in susceptibility to CRC. To
better understand what kind of impact, and at what stage
in cancer progression certain SNPs contribute to CRC sus-
ceptibility, implementing cases with both pre-malignant
and malignant neoplasia in case-control studies may be
valuable.
Many published candidate gene association studies have
assessed cancer risk by examining a single SNP per gene or
a single locus at a time analysis approach. It has been sug-
gested that use of haplotypes in association studies may
have increased power over single-allele studies [4]. Haplo-
type analyses take into account a number of tightly linked
markers, which are much more informative than individ-
ual markers. Haplotype analyses can identify unique chro-
mosomal segments likely to harbor disease predisposing
genes. Recently, a region in chromosome 19q13.2-3
encompassing the genes ERCC1, ASE-1 and RAI was iden-
tified as a high-risk haplotype, defined as homozygous
carriers of a haplotype consisting of ERCC1 Asn118AsnA,
ASE-1  G-21AG and  RAI  IVS1 A4364GA. This haplotype
consisting of three marker SNPs, is shown to be strongly
associated with increased risk of skin cancer [5], breast
cancer [6] and lung cancer [7] when compared to persons
that are not homozygous carriers of the haplotype. No
association has been observed with testicular cancer [8]. It
is possible that this high-risk haplotype would be associ-
ated with risk of colorectal cancer because it seems to be a
marker of general mechanisms affecting several cancer
forms. The region of chromosome 19 seems to be
involved in the balance between growth and elimination
of DNA damage and unwanted cells [8].
The ERCC1 gene encodes a subunit of the nucleotide exci-
sion repair complex required for the incision step of
nucleotide excision repair (NER) [9,10]. Since the ERCC1
protein is essential for NER and influence genomic insta-
bility, polymorphisms in ERCC1 may play a role in car-
cinogenesis.
The ASE-1 gene (Anti Sense ERCC1) also called CD3EAP
(CD3e antigen, epsilon polypeptide associated protein),
encodes a nucleolar protein localized to fibrillar centers of
the nucleolus and to the nucleolus organizer region of
mitotic chromosomes [11]. The mouse homolog of ASE-1
is part of the RNA polymerase I complex [12].
The gene RAI  (RelA-associated Inhibitor) also called
iASSP and PPP1R13L, is an inhibitor of the RelA subunit
of the transcription factor NF-κB [13]. The NF-κB plays a
pivotal role in the inflammatory response and apoptosis.
It is, therefore, likely that polymorphisms affecting the
level or activity of the RelA-associated inhibitor RAI
would influence the availability of RelA, and thus modify
regulation of apoptosis.
In the present paper, we aimed to evaluate whether the
recently identified haplotype encompassing genes of DNA
repair and apoptosis, is associated with increased risk of
colorectal adenomas and carcinomas in a homogenous
Norwegian cohort. In addition we investigated whether
polymorphisms in these genes alone contributed to color-
ectal adenoma and carcinoma risk. To the best of our
knowledge this high-risk haplotype has not previously
been studied in relation to colorectal adenomas or carci-
nomas. Studying colorectal adenomas in addition to
colorectal cancer may give information about the risk fac-
tors in the earlier stages of carcinogenesis
Methods
The KAM cohort (Kolorektal cancer, arv og miljø) is based
on the screening group of the Norwegian Colorectal Can-
cer Prevention study (The NORCCAP study) in the county
of Telemark [14], and a series of CRC cases operated on at
Telemark Hospital (Skien) and Ulleval University Hospi-
tal (Oslo). Those invited to participate in the NORCCAP
study were 20,780 men and women, age 50–64 years old,
drawn by randomization from the population registry in
Oslo (urban) and the county of Telemark (mixed urban
and rural). They were invited to have a flexible sigmoidos-
copy screening examination with or without (1:1) an
additional faecal occult blood test (FOBT). Seven hundred
and seventy-seven individuals were excluded according to
exclusion criteria. The overall attendance rate was 65%.
The ID number for the NORCCAP study at ClinicalTri-
als.gov is I [NCT00119912] [15]. The screened cases in the
NORCCAP study selected for colonoscopy were invited to
participate in the KAM study (1044 cases agreed). During
a limited period of time, after the screening study of
NORCCAP was well established, controls (polyp free by
sigmoidoscopy) were invited to participate in the KAM
study (400 controls agreed). Written consent was
obtained from all the participants. The KAM cohort is
based on an ethnic homogenous group of Norwegian ori-
gin.
The KAM biobank consists of blood and tissue samples
from 160 CRC cases (16 identified in the NORCCAP
screening group and 144 from hospitals), 1044 individu-BMC Cancer 2006, 6:175 http://www.biomedcentral.com/1471-2407/6/175
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als identified with adenomas in the large intestine (991
high- and low-risk adenomas, 53 hyperplastic polyps)
and 400 controls, defined as individuals with normal
findings at flexible sigmoidoscopy screening. Adenoma
cases and controls were all drawn from the NORCCAP
study. All of the participants completed a questionnaire
on demographics, health status, dietary, and smoking
habits, alcohol consumption, physical exercise and occu-
pation. The questionnaire contained information on a
family history of adenomas and carcinomas, and the
included cases and controls had no known personal his-
tory of genetic predisposition. The adenocarcinomas were
collected prior to chemo- or radiotherapy treatment. Two
specialist histopathologists examined the histology of the
adenomas independently in order to determine the tumor
stage as mild, moderate or severe dysplasia. They reached
the same conclusion in all cases. The KAM study is
approved by the Regional Ethics Committee and the Data
Inspectorate.
In the present study we analyzed available blood samples
from 156 cases with adenocarcinoma, 981 cases with ade-
nomas, (i.e. 227 high-risk and 754 low-risk adenomas)
and 399 controls. The 53 hyperplastic polyps were not
included in the analysis. Diminished numbers of availa-
ble cases in the KAM biobank and analyzed cases are due
to loss of samples during preparation and/or lack of infor-
mation from questionnaires. A high-risk adenoma is
defined as an adenoma measuring = 10 mm in diameter
and/or with villous components and/or showing severe
dysplasia [14]. The distribution of gender and age among
controls and cases with colonic carcinomas and adeno-
mas are shown in Table 1.
Genomic DNA was isolated from blood samples accord-
ing to standard procedures [16] with minor modifications
as previously described [17].
Genotypes were determined on an ABI 7500 using end-
point readings or on a light cycler (Roche Molecular Bio-
chemicals, Mannheim, Germany). ERCC1  Asn118Asn
(rs#3177700) was determined on a light cycler as
described [6].ASE-1 G-21A (rs#967591) was determined
using the primers 5'-TCT GCA ACC TGG TGC GAG-3', 5'-
CCT TTC TCC TTC CAC CAA CG-3' and the probes G-
allele: 5'-FAM- AGG GTT GCC TGA GGT GTG GGT CC-
BHQ, A-allele: Yakima Yellow- AGG GTT ACC TGA GGT
GTG GGT CC-BHQ-3'. The reactions were run for 40
cycles at 15 s at 94°C, 60 s at 62°C.RAI IVS1 A4364G
(rs#1970764) was determined as described [8]. In gen-
eral, 10 μl reactions contained ca. 50 ng DNA, 5 μl Mas-
termix (Applied Biosystems, Birkerød, Denmark), 100 nM
of each probe and 900 nM of each primer. Controls were
included in each run, and 10 % of the samples were
retyped with identical results.
MiniTab Statistical Software, Release 13.1 Xtra (Minitab
Inc.) and SPSS (Statistical Packages for the Social Sci-
ences) 12.0.1 for Windows were used for the statistic cal-
culations. Odds ratios (OR) and 95 % confidence
intervals (CI) were calculated using binary logistic regres-
sion to assess the relationship between each polymor-
phism and the colorectal adenoma or carcinoma cases.
When, estimating OR for carriers of the haplotype the
comparison group was all the other remaining individu-
als, individuals who were not homozygous carriers of the
high-risk haplotype. We have previously shown that nei-
ther known heterozygotes nor possible heterozygotes are
at increased risk of breast cancer. This strongly suggests
that the haplotype is detecting a recessive marker. We have
therefore chosen only to look at homozygous carriers' vs.
the rest. All data are adjusted for age and gender.
Smoking dose and alcohol intake were also included in
the adjustment in the logistic regression analyses, but the
results did not differ from those adjusted only for age and
gender. Including smoking and alcohol parameters
resulted in lower numbers of cases and controls due to
missing data in the questionnaires. Due to this we choose
to use the data adjusted only for age and gender.
Table 1: Distributions of gender and age among controls and cases with colorectal carcinomas and adenomas.
Controls Carcinomas Adenomas, all High-risk adenomas Low-risk adenomas
No (%) No (%) No (%) No (%) No (%)
No. of subjects 399 156 981 227 754
Sexa
Male 157 (39.3) 86 (55.1) 601 (61.3) 150 (66.1) 451 (59.8)
Female 242 (60.7) 70 (44.9) 380 (38.7) 77 (33.9) 303 (40.2)
Ageb
Mean (SD) 54.2 (3.3) 67.9 (11.2) 57.3 (3.7) 57.3 (3.5) 57.3 (3.8)
a There are significant differences in the number of males and females in the control group and the case groups, p < 10-4 (test for comparison of two 
proportions).
b There are significant differences in age among the control group and the case groups, p < 10-4 (Mann-Whitney test).BMC Cancer 2006, 6:175 http://www.biomedcentral.com/1471-2407/6/175
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With 156 CRC cases and 399 controls we have a 74 %
chance (at the 5 % level) to detect an OR of 2 for the
ERCC1 polymorphism (allele frequency 0.41) and a 92 %
chance for the ASE-1  polymorphism (allele frequency
0.18) and the RAI polymorphism (allele frequency 0.20).
Results
The genotypic distribution of the three polymorphisms in
the RAI, ASE-1 and ERCC1 genes for both cases and con-
trols are shown in Table 2 [see Additional file 1]. The gen-
otype distributions for the studied polymorphisms were
all in Hardy-Weinberg equilibrium (ERCC1 Asn118Asn p
= 0.945, ASE-1 G-21A p = 0.757 and RAI IVS1 A4364G p
= 0.673), and the distributions of the alleles are in agree-
ment with those found in other Scandinavian populations
[7,8]. Table 2 [see Additional file 1] also presents the esti-
mates of relative risk associated with the three polymor-
phisms as well as the predefined haplotype.
The  RAI  polymorphism showed a trend towards risk
reduction for both adenomas and carcinomas in women.
The risk estimate was lowest but not statistically signifi-
cant for carcinoma. For adenomas the result was border-
line statistically significant, OR of 0.70 (95% CI 0.49–
1.01).
The  ASE-1  polymorphism was associated with an
increased risk of adenomas, OR of 1.39 (95% CI 1.06–
1.81), which upon stratification was apparent among
women only, OR of 1.66 (95% CI 1.15–2.39). No associ-
ation was found for carcinoma cases.
There was no significant association between the ERCC1
polymorphism and risk of colorectal adenomas and carci-
nomas.
Women who were homozygous carriers of the high risk
haplotype had an increased risk of colorectal cancer, OR
of 2.19 (95% CI 0.95–5.04) compared to all non-carriers
although the estimate was not statistically significant.
Among men an inverse association between the high-risk
haplotype and colorectal cancer was found, although the
association was not statistically significant. No associa-
tion was found with adenoma cases.
We have also tested the gene-environment interaction
between the haplotype and the three polymorphisms, and
cigarette smoking and alcohol intake, but they showed no
significant association with colorectal adenoma or carci-
noma (results not shown).
Discussion
In this case-control study we investigated whether carriers
of a specific haplotype, encompassing genes of DNA
repair and apoptosis located on chromosome 19q13.2-3,
were at increased risk of colorectal adenomas and carcino-
mas. In addition we investigated whether polymorphisms
in these genes alone contributed to colorectal adenoma
and carcinoma risk.
The high-risk haplotype has previously been shown to be
associated with increased risk in young or middle-aged
persons. For basal cell carcinoma, effects were only seen
for the age group below 50 years [5,18,19]. For lung can-
cer and breast cancer, an effect was observed for women in
the age interval 50–55 years [6,7]. We detected no associ-
ation (prior to gender stratification) among patients with
colorectal adenomas or carcinomas for the high-risk hap-
lotype. It is possible that at least the colorectal cancer
patients in this material are too old to allow a detection of
an effect. In accordance with this, no effect of the high risk
haplotype was observed for basal cell carcinoma patients
who were older than 50 years of age [20]. However, we did
detect an effect in women and an inversely effect in men
after stratifying for gender, in relation to CRC cases,
although not significant. There are indications that effect
of the haplotype may vary between the sexes because the
haplotype was associated with increased risk of breast can-
cer [6] and not with risk of testis cancer [8]. In lung cancer
Vogel et al. [21] have found statistically significant differ-
ences between sexes. Women who are homozygous carri-
ers of the haplotype are at increased risk of lung cancer
compared to men.
The polymorphism in RAI is shown to be the strongest
determinant of the haplotype [6,21]. RAI was discovered
as an inhibitor of RelA (a subunit of NF-κB) and is thus
presumably involved in the control of transcription [13],
but its function is poorly understood. RAI is involved in
control of apoptosis, and over-expression of RAI has been
shown to suppress apoptosis induced by cisplatin or UV
light [22]. Up regulation of RAI expression has been
observed in cancer cells [22,23]. Previous data suggest that
the predefined haplotype is associated with defective
apoptosis [21]. It is therefore likely that the haplotype is
linked to a functional polymorphism in RAI  which
increases the protein level of RAI, resulting in a defective
apoptosis trigger. It has previously been observed that the
polymorphism in RAI and the high risk haplotype may be
associated with cancer risk in women only [6-8]. For the
polymorphism in RAI, we have consistently found protec-
tive effect of the variant allele. For lung cancer, however, it
was found that the variant allele was protective among
women (AG: RR= 0.58, CI 0.33–1.03, GG: RR = 0.12, CI
0.01–1.04, p trend 0.007), while no protective effect was
observed for men (AG: 1.79, CI 1.12–2.87, GG: RR = 0.51,
CI 0.13–2.05, Ole Raaschou-Nielsen and Ulla Vogel,
unpublished results). Here, we see the same pattern.
Among women, carriers of the variant allele of RAI IVS1
A4364G were at reduced risk of both colorectal cancerBMC Cancer 2006, 6:175 http://www.biomedcentral.com/1471-2407/6/175
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(OR= 0.49, CI 0.21–1.13) and adenomas (OR = 0.70, CI
0.49–1.01). Vogel et al. [24] have shown that the RAI
mRNA level is 41 % higher in lymphocytes from women
compared to men, which may indicate that a gender dif-
ference could be due to variation in transcription levels
which subsequently result in differences in protein level.
A possible explanation for our gender specific findings
could be that women who are homozygous carriers of the
haplotype have a defective apoptosis trigger (high levels
of RAI). Colon cells with excessive DNA damage do not
undergo apoptosis but survive with the potential of subse-
quent malignant transformation.
Very little is known about the function of ASE-1. White-
head et al. [11] identified the ASE-1 gene product as a
nucleolar protein by screening a HeLa cDNA library with
a human autoimmune serum. The mouse Pol I-associated
factor PAF49 shows striking homology to the human
nucleolar protein ASE-1. Immunolocalization analysis
revealed that PAF49 accumulated in the nucleolus of
growing cells but dispersed to nucleoplasma in growth-
arrested cells. These results strongly suggest that PAF49/
ASE-1 plays an important role in rRNA transcription [12].
Involvement in the immune function of this gene product
has also been suggested [25]. We found that the observed
risk estimate was highest among the heterozygote carriers,
which may suggest that we detect an effect of another,
linked polymorphism. The fact that we observe an effect
for adenomas but not for colorectal cancer makes a
chance finding possible. Another explanation for the
observed association in the adenoma group only could be
that the polymorphism may play a role in regression of
adenomas rather than in progression to cancer.
The CRC cases and controls have not been matched by age
which may affect the results in a study. However, the con-
trols were recruited from the same cohort as the adenoma
and carcinoma cases. The adenoma cases and controls are
from 50 to 64 years of age. Further, our controls have been
screened and found polyp free and the risk of any of them
having colon cancer at the time of inclusion is not very
likely.
Taking the number of statistical tests performed and the p-
values we cannot exclude that our findings are due to
chance. The relatively small numbers of the CRC cases
limited our power to detect and association with carcino-
mas. However, the findings for RAI are consistent with
previous findings [5-8].
Conclusion
The high-risk haplotype is not associated with increased
risk of adenomas or colorectal cancer prior to gender strat-
ification. When stratifying for gender, we did detect an
effect in women and an inverse effect in men in relation
to CRC cases, although not significant. Of the high-risk
haplotype markers, the ASE-1 polymorphism was associ-
ated with an increased risk of adenomas in women. The
RAI polymorphism showed a trend towards risk reduction
for both adenomas and carcinomas in women, although
not significant. There was no significant association
between the ERCC1 polymorphism and risk of colorectal
adenomas and carcinomas. In conclusion we found no
evidence that the studied polymorphisms were associated
with risk of adenomas or colorectal cancer among men,
but we found weak indications that the chromosomal
region may influence risk of colorectal cancer and ade-
noma development in women.
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